Literature DB >> 24293417

Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?

Shashikant Srivastava1, Charles A Peloquin, Giovanni Sotgiu, Giovanni Battista Migliori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24293417     DOI： 10.1183/09031936.00073213

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  13 in total

1.  The multidrug-resistant tuberculosis threat: old problems and new solutions.

Authors:  Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Ida Mura; Paolo Castiglia; Antonio Spanevello; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Authors:  Adrian Rendon; Simon Tiberi; Anna Scardigli; Lia D'Ambrosio; Rosella Centis; Jose A Caminero; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Xin Zhang; Matthew E Falagas; Konstantinos Z Vardakas; Rui Wang; Rong Qin; Jin Wang; Youning Liu
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

4.  Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry.

Authors:  Jan-Willem C Alffenaar; Mathieu Bolhuis; Kai van Hateren; Marieke Sturkenboom; Onno Akkerman; Wiel de Lange; Ben Greijdanus; Tjip van der Werf; Daan Touw
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

5.  Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.

Authors:  V Mave; A Chandanwale; A Kinikar; S Khadse; A Kagal; N Gupte; N Suryavanshi; S Nimkar; H Koli; S Khwaja; R Bharadwaj; S Joshi; H Horng; L Z Benet; G Ramachandran; K E Dooley; A Gupta; M Gandhi
Journal:  Int J Tuberc Lung Dis       Date:  2016-06       Impact factor: 2.373

6.  Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.

Authors:  Simone H J van den Elsen; Marieke G G Sturkenboom; Onno W Akkerman; Katerina Manika; Ioannis P Kioumis; Tjip S van der Werf; John L Johnson; Charles Peloquin; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 7.  Tuberculosis treatment and drug regimens.

Authors:  Giovanni Sotgiu; Rosella Centis; Lia D'ambrosio; Giovanni Battista Migliori
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-08       Impact factor: 6.915

Review 8.  Understanding pharmacokinetics to improve tuberculosis treatment outcome.

Authors:  Jonathan Reynolds; Scott K Heysell
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-03-06       Impact factor: 4.481

9.  Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

Authors:  Simone H J van den Elsen; Marieke G G Sturkenboom; Natasha Van't Boveneind-Vrubleuskaya; Alena Skrahina; Tjip S van der Werf; Scott K Heysell; Stellah Mpagama; Giovanni B Migliori; Charles A Peloquin; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

10.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.